Via practica 4/2007

STRONTIUM RANELATE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS

Vertebral and nonvertebral fractures may have important impact on quality of life in patients suffering from osteoporosis. To reduce the risk of fractures, in clinical practics, we use several medicaments which are characterised by bone turnover decreasing. They decrease both bone formation and bone resorption with different intensity. Strontium ranelate is medicament with different, so called, dual effects on bone turnover, which supress bone resorption and stimulates bone formation. Autors present short overview of the mode of action of othe drug and results of the most important clinical trials with accent on effectivity and safety in the clinical praxis.

Keywords: strontium ranelate, osteoporosis, fractures.